Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
Lite Strategy, Inc., formerly MEI Pharma, reports developments tied to its transition from a clinical-stage pharmaceutical issuer into a public-company digital asset treasury business. News has centered on the adoption of Litecoin (LTC) as the company’s primary treasury reserve asset, the completed corporate rebrand and Nasdaq ticker change from MEIP to LITS, and capital actions used to fund the strategy.
Company updates also cover treasury-management relationships, governance changes, and historical MEI Pharma disclosures involving cash preservation, strategic alternatives, and oncology drug candidates such as voruciclib and ME-344.
MEI Pharma, Inc. (NASDAQ: MEIP) has announced it will release its 2021 fiscal year-end financial results on September 2, 2021, after market close. A conference call to discuss the results and provide a corporate update will be held at 5:00 p.m. ET on the same day. Investors can join the call by dialing 1-833-974-2378 in the U.S. or 1-412-317-5771 internationally. The call will also be accessible via a live webcast on MEI Pharma's investor relations website.
MEI Pharma and Kyowa Kirin announced the dosing of the first patient in the Phase 3 COASTAL study, evaluating zandelisib, a selective PI3Kδ inhibitor, alongside rituximab for relapsed or refractory follicular and marginal zone lymphomas. This study aims to enroll 534 patients and will compare zandelisib plus rituximab to standard chemotherapy. The primary endpoint is progression-free survival, with the results intended to support marketing applications for zandelisib in the U.S. and globally.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the retirement of CFO Brian Drazba, effective end of 2021, after serving since April 2017. Drazba has been pivotal in enhancing the company's financial infrastructure and will support the transitional phase. MEI Pharma is actively searching for a new CFO. The company specializes in developing cancer therapies, with a pipeline that includes four clinical-stage drug candidates, such as zandelisib, currently undergoing multiple trials to gain regulatory approvals.
MEI Pharma, Inc. (NASDAQ: MEIP) has announced the granting of inducement stock options for 306,000 shares to seven new employees, aimed to attract talent. The options, priced at $2.70, match the stock's closing price on the grant date and are part of MEI's 2021 Inducement Grant Equity Compensation Plan. They will vest over a period of time with a term of 10 years. This move aligns with Nasdaq Listing Rule 5635(c)(4), requiring prompt disclosure via press release. The company continues to focus on developing new cancer therapies, with zandelisib undergoing a Phase 2 clinical trial.
MEI Pharma (NASDAQ: MEIP) has appointed Tina C. Beamon, J.D., as chief compliance officer to oversee compliance programs. Beamon brings over 20 years of experience from the healthcare and pharmaceutical sectors, having previously held leadership roles at Karyopharm Therapeutics and Alexion Pharmaceuticals. Her expertise is expected to strengthen MEI's compliance as the company prepares for the commercialization of its lead drug candidate, zandelisib, currently in Phase 2 trials.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of inducement stock options for 169,000 shares to three new employees. The options have an exercise price of $2.85, equal to the stock's closing price on the grant date. Approved by the Compensation Committee, these options vest gradually over ten years. MEI Pharma focuses on developing cancer therapies, with clinical-stage assets like zandelisib. The press release notes potential risks associated with FDA approvals and market acceptance, highlighting the uncertainties of drug development.
MEI Pharma (NASDAQ: MEIP) and Kyowa Kirin announced clinical data from a Phase 1b study evaluating zandelisib, a selective PI3K delta inhibitor for treating B-cell malignancies. The data will be showcased at the 16th International Conference on Malignant Lymphoma from June 18-22, 2021. The study aims to address patients with follicular lymphoma who progressed within 24 months of first-line therapy. Additionally, the Phase 3 COASTAL study will investigate zandelisib combined with rituximab versus conventional therapies for relapsed or refractory indolent non-Hodgkin's lymphoma.
MEI Pharma and Kyowa Kirin have initiated the second arm of the global Phase 2 TIDAL study, dosing the first patient with relapsed or refractory marginal zone lymphoma. This arm evaluates zandelisib, a PI3K delta inhibitor, alongside a previous arm focusing on follicular lymphoma. Both arms aim for separate FDA accelerated approval applications. The study will assess objective response rates and tolerability of zandelisib. This collaboration between the companies highlights their commitment to advancing therapeutic options for patients with B-cell malignancies.
MEI Pharma, Inc. (NASDAQ: MEIP) will host a video webcast for investors and analysts on June 10, 2021, at 12:00 PM ET, following the 2021 ASCO Annual Meeting. The event will cover updates on the zandelisib program, including data presented at ASCO, with insights from Dr. Deepa Jagadeesh of the Cleveland Clinic. The webcast can be accessed on MEI's investor relations website, and a replay will be available for 30 days. MEI focuses on developing innovative cancer therapies and has four clinical-stage assets, including zandelisib, which is in a Phase 2 trial.
On May 19, 2021, MEI Pharma announced promising data for zandelisib, a PI3Kδ inhibitor, aimed at treating B-cell malignancies. Key findings include an 87% overall response rate in relapsed or refractory follicular lymphoma patients, with 93% in non-POD24 patients. The Phase 3 COASTAL study, comparing zandelisib plus rituximab to standard chemotherapy in indolent non-Hodgkin's lymphoma, is set to enroll 534 patients. Topline results from the ongoing Phase 2 TIDAL study are expected later this year, reinforcing the commitment to zandelisib's development as a potential best-in-class therapy.